JP2005520523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005520523A5 JP2005520523A5 JP2003577595A JP2003577595A JP2005520523A5 JP 2005520523 A5 JP2005520523 A5 JP 2005520523A5 JP 2003577595 A JP2003577595 A JP 2003577595A JP 2003577595 A JP2003577595 A JP 2003577595A JP 2005520523 A5 JP2005520523 A5 JP 2005520523A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- antigen
- binding portion
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000056 organ Anatomy 0.000 claims description 5
- 102000015212 Fas Ligand Protein Human genes 0.000 claims description 4
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000008383 multiple organ dysfunction Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36705402P | 2002-03-21 | 2002-03-21 | |
| US40976802P | 2002-09-10 | 2002-09-10 | |
| PCT/US2003/006155 WO2003079750A2 (en) | 2002-03-21 | 2003-03-12 | ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005520523A JP2005520523A (ja) | 2005-07-14 |
| JP2005520523A5 true JP2005520523A5 (enExample) | 2006-04-20 |
Family
ID=28457146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003577595A Pending JP2005520523A (ja) | 2002-03-21 | 2003-03-12 | アンタゴニスト的抗ｈＦａｓリガントヒト抗体およびそのフラグメント |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7262277B2 (enExample) |
| EP (1) | EP1490405B1 (enExample) |
| JP (1) | JP2005520523A (enExample) |
| CN (1) | CN1283662C (enExample) |
| AT (1) | ATE370970T1 (enExample) |
| AU (1) | AU2003219954B2 (enExample) |
| BR (1) | BR0308401A (enExample) |
| CA (1) | CA2478386A1 (enExample) |
| DE (1) | DE60315815T2 (enExample) |
| DK (1) | DK1490405T3 (enExample) |
| ES (1) | ES2291626T3 (enExample) |
| IL (1) | IL164011A0 (enExample) |
| MX (1) | MXPA04009148A (enExample) |
| PT (1) | PT1490405E (enExample) |
| WO (1) | WO2003079750A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| ME01775B (me) * | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| DK1766093T3 (da) | 2004-02-06 | 2011-10-03 | Univ Massachusetts | Antistoffer mod clostridium difficile-toksiner og anvendelse deraf |
| WO2007031875A2 (en) * | 2005-08-26 | 2007-03-22 | Glycart Biotechnology Ag | Modified antigen binding molecules with altered cell signaling activity |
| RU2558260C2 (ru) * | 2007-12-12 | 2015-07-27 | Пинчел Срл | ЛЕКАРСТВЕННЫЕ СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ ПЕМФИГУСА, СОДЕРЖАЩИЕ АНТИТЕЛА К Fas-ЛИГАНДУ |
| EP2318441A2 (en) * | 2008-07-14 | 2011-05-11 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
| PT2376536E (pt) * | 2008-12-12 | 2015-05-11 | Pincell Srl | Remédios para pênfigo contendo anticorpos anti-ligando de faz |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| EP2951589A1 (en) * | 2013-02-01 | 2015-12-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting and preventing metastasis in triple negative breast cancers |
| BR112015027249A2 (pt) * | 2013-04-29 | 2017-09-26 | Apogenix Gmbh | método de diagnóstico de câncer |
| EP3137909B1 (en) * | 2014-04-29 | 2018-06-06 | Apogenix AG | Diagnostic anti-cd95l antibody |
| US20220289827A1 (en) * | 2021-03-11 | 2022-09-15 | Washington University | Neutralizing antibodies to sars-cov-2 and its variants |
| CN116888257A (zh) * | 2022-01-21 | 2023-10-13 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
| WO2023138522A1 (zh) * | 2022-01-21 | 2023-07-27 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
| EP4514388A1 (en) | 2022-04-26 | 2025-03-05 | F. Hoffmann-La Roche AG | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist |
| WO2024193714A1 (zh) * | 2023-03-23 | 2024-09-26 | 科济生物医药（上海）有限公司 | 细胞免疫疗法的组合物和方法 |
| EP4474395A1 (en) * | 2023-06-06 | 2024-12-11 | PinCell S.r.l. | Anti-fas ligand (fasl) antibodies in the treatment of sjs/ten diseases |
| AU2024248262A1 (en) * | 2023-03-24 | 2025-09-25 | Pincell S.R.L. | Anti-fas ligand (fasl) antibodies in the treatment of sjs/ten diseases |
| WO2025196289A1 (en) | 2024-03-22 | 2025-09-25 | Pincell S.R.L. | New target affinity and specificity of anti sfas-l antibody, pc111 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08127594A (ja) | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ |
| EP0739350B1 (en) | 1994-01-07 | 2008-02-27 | Mochida Pharmaceutical Co., Ltd. | Ligand that binds fas antigen |
| US6096312A (en) * | 1995-06-30 | 2000-08-01 | Mochida Pharmaceutical Co., Ltd. | Agent for suppressing a reduction of CD4+ lymphocytes |
| US6114507A (en) * | 1995-06-30 | 2000-09-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
| JP3925663B2 (ja) * | 1995-06-30 | 2007-06-06 | 持田製薬株式会社 | 抗Ｆａｓリガンド抗体および該抗体を用いた測定法 |
-
2003
- 2003-03-12 DE DE60315815T patent/DE60315815T2/de not_active Expired - Lifetime
- 2003-03-12 CN CNB038064030A patent/CN1283662C/zh not_active Expired - Fee Related
- 2003-03-12 EP EP03716239A patent/EP1490405B1/en not_active Expired - Lifetime
- 2003-03-12 MX MXPA04009148A patent/MXPA04009148A/es active IP Right Grant
- 2003-03-12 PT PT03716239T patent/PT1490405E/pt unknown
- 2003-03-12 JP JP2003577595A patent/JP2005520523A/ja active Pending
- 2003-03-12 WO PCT/US2003/006155 patent/WO2003079750A2/en not_active Ceased
- 2003-03-12 BR BR0308401-9A patent/BR0308401A/pt not_active IP Right Cessation
- 2003-03-12 CA CA002478386A patent/CA2478386A1/en not_active Abandoned
- 2003-03-12 IL IL16401103A patent/IL164011A0/xx unknown
- 2003-03-12 ES ES03716239T patent/ES2291626T3/es not_active Expired - Lifetime
- 2003-03-12 AU AU2003219954A patent/AU2003219954B2/en not_active Ceased
- 2003-03-12 US US10/506,743 patent/US7262277B2/en not_active Expired - Fee Related
- 2003-03-12 AT AT03716239T patent/ATE370970T1/de not_active IP Right Cessation
- 2003-03-12 DK DK03716239T patent/DK1490405T3/da active